Delhi · Gurugram · Bangalore · Baddi · Bahadurgarh

Bioburden Testing for Medical Devices

Every sterile medical device reaching the market requires validated sterilisation — and the sterilisation dose can only be determined from accurate pre-sterilisation bioburden data. Auriga Research provides NABL-accredited bioburden testing per ISO 11737-1, supporting sterilisation validation dossiers accepted by CDSCO, FDA 510(k), and CE Notified Bodies.

Our scope covers total aerobic microbial count (TAMC) and total yeast and mould count (TYMC) per ISO 11737-1, recovery efficiency validation (repetitive and corrective), microbial identification by biochemical and molecular methods, routine batch-release bioburden, and bioburden trending for SPC. Bioburden data feeds directly into ISO 11137 VDmax dose-setting for radiation sterilisation and ISO 11135 cycle development for EO sterilisation — delivering the SAL 10⁻⁶ that regulators require.

Backed by the Arbro Group's analytical heritage — Arbro Lab since 1990, Auriga Research since 2007 — with NABL ISO/IEC 17025 accreditation, our reports are accepted by CDSCO licensing authorities, FDA 510(k) reviewers, EU CE Notified Bodies, and contract sterilisers running ISO 11137 dose audits.

Reports in 7–10 working days | Routine batch release: 7 days

Get a Quote Call +91-7428116100

Bioburden Testing Scope

Each capability is mapped to its ISO 11737-1 method or workflow so sterility-assurance and QA teams can match scope to the validation dossier at a glance.

ISO 11737-1

Total Aerobic Count (TAMC)

Total aerobic microbial count per ISO 11737-1 — the core enumeration feeding sterilisation dose-setting.

TYMC

Yeast & Mould Count

Total yeast and mould count to characterise the fungal fraction of the bioburden population.

Recovery

Recovery Efficiency Validation

Repetitive and corrective recovery efficiency determination to prove the extraction method recovers a known proportion of organisms.

16S / 18S

Microbial Identification

Genus / species identification by biochemical and molecular (16S / 18S rRNA) methods for dose audits and excursion investigations.

Batch Release

Routine Monitoring

Routine bioburden monitoring for production batch release to confirm the established sterilisation dose remains adequate.

SPC

Trending & SPC

Bioburden trending and statistical process control analysis for ongoing process control.

Components

Raw Material Bioburden

Incoming raw material and component bioburden assessment for OEM and supplier specifications.

SIP

Sample-Item Portion

Sample-item portion (SIP) determination per ISO 11737-1 Annex C for large or complex devices.

How It Works

Get a Quote

Share your device type, sterilisation method, and regulatory target (CDSCO / FDA / CE). Your dedicated SPOC confirms the testing scope, the applicable ISO 11737-1 protocol, and the sample-item portion (SIP) required for your specific device before you dispatch anything.

Send Your Sample

Dispatch sterile-handled device samples with a completed Test Request Form to the nearest Auriga lab. Each sample is individually bar coded and registered in YLIMS, Auriga's in-house Laboratory Information Management System, upon receipt. Testing begins within 24 hours of sample registration.

Testing and QA Review

Your sample is tested per the validated ISO 11737-1 method by Auriga's microbiology team in our clean-room facility. Every enumeration result passes through a formal internal QA review and sign-off before the report is generated.

Receive Your NABL Report

Your NABL-accredited bioburden test report is delivered digitally within the committed turnaround time. Reports carry Auriga's NABL accreditation under ISO/IEC 17025:2017 and are accepted by CDSCO, FDA 510(k), CE Notified Bodies, and contract sterilisers for ISO 11137 / 11135 dose audits. You can track sample status in real time through YLIMS at any point in the process.

Turnaround Time

Service	Standard TAT	Express
Bioburden enumeration (TAMC + TYMC) per ISO 11737-1	7–10 business days	Available
Routine batch release bioburden	7 business days	Available
Recovery efficiency validation	15–20 business days	On request
Microbial identification (biochemical / 16S rRNA)	+ 5–7 business days	Available
Sample-item portion (SIP) determination	10–14 business days	On request

Who Needs Bioburden Testing

Medical device manufacturers establishing sterilisation validation for CDSCO / FDA / CE submission under ISO 11135 (EO) or ISO 11137 (radiation).
Contract sterilisers requiring routine bioburden data for ISO 11137 VDmax dose audits and EO cycle re-qualification.
Quality teams running routine production bioburden monitoring and trending for process control (SPC).
Class C / Class D implant manufacturers (orthopaedic, cardiovascular, ophthalmic) building dossiers for high-risk device approvals.
Single-use device manufacturers (syringes, catheters, IV sets, wound dressings) verifying batch bioburden before sterilisation release.
CDSCO regulatory consultants assembling device master files and sterilisation validation packages on behalf of manufacturer clients.
Component and raw material suppliers needing incoming bioburden specifications for OEM device manufacturers.
Reprocessing and refurbishing facilities verifying bioburden control on reusable medical devices and surgical instruments.

Why Auriga for Bioburden Testing

NABL ISO/IEC 17025:2017 scope includes ISO 11737-1

Bioburden testing is explicitly in our NABL scope certificate — not a derivative or extension — which means CDSCO, FDA, and CE Notified Bodies accept the report without follow-up scope verification.

Clean-room microbiology facilities

Dedicated clean-room enumeration suites with environmental monitoring under ISO 14644 control — eliminates false-positive recovery from lab air, the most common audit finding on bioburden reports from non-specialist labs.

Microbial identification in the same lab

GC-MS, LC-MS, biochemical (Vitek / API), and molecular (16S / 18S rRNA) identification all in-house — no sample transfer delays when an unusual isolate needs characterisation for a dose audit or excursion investigation.

Validated for EO and radiation sterilisation

Bioburden data formatted for direct use in ISO 11137 VDmax dose-setting (radiation) and ISO 11135 microbiological performance qualification (EO) — pre-configured for the most common regulatory submission paths.

CDSCO / FDA / CE acceptance trail

Reports routinely accepted in CDSCO Form MD-9 / MD-15 submissions, FDA 510(k) sterility sections, and CE technical files reviewed by major Notified Bodies (BSI, TÜV SÜD, DEKRA, DNV).

Arbro Group analytical heritage

Established analytical heritage through the Arbro Group (Arbro Lab since 1990, Auriga Research since 2007), with NABL ISO/IEC 17025 accreditation — the audit trail medical device manufacturers, contract sterilisers, and regulatory consultants look for in a microbiology partner.

Related Services

Frequently Asked Questions

What is bioburden testing and why is it required for medical devices?

Bioburden testing determines the total number of viable microorganisms on a medical device prior to sterilisation. Per ISO 11737-1, bioburden data is essential for establishing and validating sterilisation processes — it defines the microbial challenge the sterilisation cycle must overcome. CDSCO, FDA, and CE marking all require bioburden testing as part of the sterilisation validation dossier for medical devices.

How is bioburden testing performed per ISO 11737-1?

The device or representative portion is subjected to extraction using rinse, sonication, or stomaching techniques to remove microorganisms from surfaces. The extract is then cultured on appropriate media (TSA for bacteria, SDA for fungi) and incubated at prescribed temperatures. Colony counts represent the bioburden level. Method validation — including recovery efficiency determination — must be performed to demonstrate the extraction technique recovers a known proportion of organisms.

What is an acceptable bioburden level for medical devices?

There is no universal pass/fail bioburden limit — acceptable levels depend on the sterilisation method and required Sterility Assurance Level (SAL). For EO and radiation sterilisation, bioburden data feeds into dose-setting calculations (e.g., ISO 11137 VDmax method). Devices with consistently low bioburden (under 10 CFU) can qualify for lower sterilisation doses. Monitoring bioburden trends over production batches is equally important for process control.

What sample quantity is required for an ISO 11737-1 bioburden programme?

Sample quantity depends on the device size and complexity, the sample-item portion (SIP) selected, and the test scope. Routine batch-release bioburden typically requires 10 to 20 finished devices or device portions. Recovery efficiency validation needs an additional 30 to 50 units across the inoculated, recovered, and corrective factor test arms. Microbial identification of recovered isolates uses 1-2 g of isolated culture, no additional device sample needed. For large or complex devices where extracting the whole device is impractical, a representative SIP is determined first (ISO 11737-1 Annex C) — this itself requires 10-15 units to establish. Confirm the exact quantity with your SPOC during the quote step before despatch, particularly for high-value implantable devices where sample destruction has a material cost.

What is the regulatory consequence of inadequate bioburden data on a sterilisation validation dossier?

Bioburden gaps directly attack the foundation of a sterilisation validation. (1) CDSCO: an MD-9 / MD-15 application without ISO 11737-1 bioburden data and ISO 11137 VDmax (radiation) or ISO 11135 (EO) cycle development data will be returned with a sterilisation-validation deficiency — typically blocking the registration timeline by 3-6 months. (2) FDA 510(k): the Sterilisation Provisions section requires bioburden data and dose-setting evidence; an Additional Information (AI) request on this section pauses substantial equivalence review. (3) CE MDR: Notified Body non-conformances on sterilisation validation are among the top three reasons for CE technical file rejection — manufacturers commonly need 4-12 weeks of additional testing to close. (4) Post-market: a sterility failure in distributed product triggers CDSCO Materiovigilance / FDA MAUDE reporting and a full recall — and the root-cause investigation almost always demands historical bioburden trend data. Building a routine bioburden monitoring programme is materially cheaper than reacting to a sterility incident.

How often should I run routine bioburden monitoring? When does the sterilisation dose need re-qualification?

ISO 11737-1 and the sterilisation-method standards (ISO 11137 for radiation, ISO 11135 for EO) require periodic bioburden monitoring to confirm the established sterilisation dose remains adequate. Default frequency is quarterly bioburden monitoring (one batch per quarter) for stable production. Re-qualification of the sterilisation dose is required under ISO 11137 when: (a) the routine bioburden trend exceeds the established alert/action limits; (b) the bioburden microbial population characterisation changes (e.g., a new dominant organism); (c) manufacturing process, materials, or supplier changes occur; (d) the product design changes in a way that affects surface area or extractable load; (e) bioburden audits (typically annually under ISO 11137 dose audit, every 3 months until established) indicate the dose is no longer adequate. Auriga supports both routine monitoring programmes and the formal dose audit / re-qualification testing.

Can Auriga support contesting a CDSCO or Notified Body finding on sterilisation validation with additional bioburden data?

Yes. Gap-fill bioburden testing in response to a CDSCO deficiency letter, an FDA AI request on the Sterilisation Provisions section, or a Notified Body non-conformance on the sterilisation validation is a routine workflow. The path is: (1) review the regulator's specific finding with your SPOC; (2) identify whether the gap requires additional routine bioburden batches, a recovery efficiency re-validation, microbial identification of historical isolates, or a fresh dose audit; (3) run the targeted top-up programme — not a full re-validation; (4) issue an NABL-accredited supplementary bioburden report formatted as an addendum to the original sterilisation validation. Express 48-72 hour turnaround is available for time-critical regulatory response windows.

Get a Tailored Recommendation

Talk to a Testing Expert